Monoamine oxidase inhibitors for IgA nephropathy

Medical Hypotheses

Volumn 56, Issue 2, 2001, Pages 225-226

  Altschuler, E L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MONOAMINE OXIDASE INHIBITOR; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COLON CROHN DISEASE; DRUG USE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MESANGIUM; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STEROID THERAPY;

GYMNOMYZA SAMOENSIS;

EID: 0035094045     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1158     Document Type: Article

References (15)

1. IgA nephropathy
2. Treatment of immunoglobulin A nephropathy
3. Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors
4. Does phenelzine relieve aphthous ulcers of the mouth?
5. Crohn's disease remission with phenelzine treatment
6. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
7. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
8. Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis
9. Molecular pharmacology of the beta-adrenergic receptor on THP-1 cells
10. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
11. Catecholamines increase monocyte TNF receptors and inhibit TNF through beta 2 adrenoreceptor activation
12. Release of tumor necrosis factor-alpha from coronary smooth muscle: Activation of NF-kappaB and inhibition by elevated cyclic AMP
13. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
14. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram
15. Imbalances in serum proinflammatory cytokines and their soluble receptors: A putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy?